Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Episode Description
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.